Marvel Biosciences signs CRO deal for phase 1 autism drug trial
Investing.com India
Marvel Biosciences has signed a contract with a contract research organization (CRO) to conduct a phase 1 clinical trial for its autism drug. The trial aims to evaluate the safety and efficacy of the drug in treating autism spectrum disorder. This partnership marks a significant step in the development of the drug towards potential market approval.
All articles from 6 October 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.